Form 4: Baker Bros. Advisors Reports TScan Director Option Grant

Baker Bros. Advisors disclosed a grant of 67,000 stock options to TScan Therapeutics director Dr. Stephen R. Biggar.

Summary

• Dr. Stephen R. Biggar, a director at TScan Therapeutics and employee of Baker Bros. Advisors, was granted 67,000 non-qualified stock options.
• The options were granted on May 20, 2026, with a strike price of $0.9946 per share.
• The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.
• The options expire on May 19, 2036.
• Baker Bros. Advisors and its affiliated funds maintain an indirect pecuniary interest in these securities per internal policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, carrying no significant change in company fundamentals.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized equity incentive plan usage for board compensation.

Negatives

• Dilutive impact of 67,000 new stock options on existing shareholders.

Risks

• Potential for future dilution if options are exercised.
• Dependence on Dr. Biggar's continued service on the Board for the vesting of these options.

Future Outlook

The options vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, provided the director remains in service.

Management Comments

• The reporting persons are deemed directors by deputization of the Issuer by virtue of their representation on the board.

Industry Context

StockSavvy.ai notes that equity grants to board members representing institutional investors are standard practice in the biotechnology sector to ensure alignment, though they contribute to ongoing share dilution.

Comparison to Industry Standards

• The use of 10-year expiration terms for director stock options is consistent with standard biotech industry compensation practices.
• Vesting schedules tied to annual meetings are common for non-employee directors in small-cap pharmaceutical companies.

Corporate Governance

Related Party Transactions

• Dr. Stephen R. Biggar is an employee of Baker Bros. Advisors LP, which serves as the investment adviser to the Funds holding an indirect interest in these securities.

Stakeholder Impact

• Minor dilution for existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on the earlier of May 20, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

TScan Therapeutics, TCRX, Baker Bros. Advisors, Form 4, Director Compensation, Stock Options, Insider Ownership